Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11:60:389-395.
doi: 10.1016/j.amsu.2020.11.013. eCollection 2020 Dec.

P2X3 receptor expression in dorsal horn of spinal cord and pain threshold after estrogen therapy for prevention therapy in neuropathic pain

Rohadi Muhammad Rosyidi  1 , Bambang Priyanto  1 , Dewa Putu Wisnu Wardhana  2 , Krisna Tsaniadi Prihastomo  3 , Syauq Hikmi  4 , Agus Turchan  5 , Rozikin  6
Affiliations

P2X3 receptor expression in dorsal horn of spinal cord and pain threshold after estrogen therapy for prevention therapy in neuropathic pain

Rohadi Muhammad Rosyidi et al. Ann Med Surg (Lond). .

Abstract

Introduction: Neuropathic pain may arise from conditions that affecting the central or peripheral nervous system. This study was held to determine the difference P2X3 receptor expression in the dorsal horn of the spinal cord and pain threshold after estrogen therapy in neuropathic pain.

Methods: This study design was an experimental research laboratory. The 24 mice samples divided into negative control group, positive control, and treatment groups. The treatment groups were given subcutaneous injections of estrogen 0.4 ml and also examined for the onset of thermal hyperalgesia in every rat. On day 15, an autopsy was performed on rats, and the spine was taken. The spinal cord was stained by hematoxylin-eosin, and the expression of P2X3 receptors was investigated. P2X3 receptor expression was examined in the dorsal horn on each sample.

Results: From 24 subjects of the study revealed an increase in the onset of thermal hyperalgesia on the estrogen group compared with the placebo group, a higher start. This study also obtained a decrease in the expression of P2X3 on the therapy group compared to the positive control group with significant differences. Statistical test results revealed the appearance of the P2X3 estrogen group had a substantial difference with the placebo group (p = 0.000) and the mean of the negative control group (p = 0.030). The placebo group had a significant difference from the negative control group (p = 0.035).

Conclusion: Estrogen could decrease the expression of P2X3 receptors and prolonged the onset of thermal hyperalgesia. So, both of these explained that estrogen has a role in preventing the occurrence of neuropathic pain after peripheral nerve lesions.

Keywords: Estrogen; Neuropathic pain; P2X3 receptor; Prevention therapy; Thermal hypealgesia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
Transverse slices of rat spinal cord with HE staining.
Fig. 2
Fig. 2
Receptor expression in rat spinal cord (200× magnification).
Fig. 3
Fig. 3
The effect of ligation on mice sensitivity to warm plate stimulus.
Fig. 4
Fig. 4
Graph boxplot comparison of P2X3 expressions for each group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Marcus D.A., Core D.K., Deodhar A., Payne R. Clinical Publising Oxford; Oxon UK: 2009. An Atlas of Investigation and Management Chronic Pain; pp. 1–14.
    1. Jorge Carolina Ocanha. P2X3 receptors contribute to transition from acute to chronic muscle pain. Purinergic Signal. 2020:1–12. - PMC - PubMed
    1. Sinanović O. Neuropathic pain. Acta Clin. Croat. 2010;49(Suppl) No. 2.
    1. Grinsell D., Keating C.P. Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies. BioMed Res. Int. 2014 - PMC - PubMed
    1. Alles Sascha RA., Smith Peter A. Etiology and Pharmacology of neuropathic pain. Pharmacol. Rev. 2018;70(2):315–347. - PubMed